Fig. 3

ITGB4 and APOL1 inhibition sensitizes cells overexpressing ANGPTL4 to gemcitabine. a-b) Kaplan-Meier plot for overall survival using TCGA-PAAD data. Patients with the top (red) and bottom (blue) 25% average ANGPTL4 gene expression and APOL1 or ITGB4 gene expression (p = 0.01 and p = 0.014, respectively, log-rank test). c) ANGPTL4 expression measured by qPCR normalized to MP2_ANGPTL4_OE + DsiRNA_NTC (turquoise) control: MP2 (pink), MP2_ANGPTL4_OE_ITGB4_KD (lavender), and MP2_ANGPTL4_OE_APOL1_KD (purple) compared to mean of MP2_ANGPTL4_OE + DsiRNA_NTC (MP2_ANGPTL4_OE cells transduced with non-targeting control siRNA). Expression is normalized to the housekeeping gene ACTB. P-values ≤ 0.0001=****; unpaired two-tailed parametric t-test d) Relative viability is plotted by normalizing all data to cells not treated with gemcitabine. MP2_ANGPTL4_KD (black), MP2_NTC (pink), MP2_ANGPTL4_OE + DsiRNA_NTC (turquoise), MP2_ANGPTL4_OE_ITGB4_KD (lavender), and MP2_ANGPTL4_OE_APOL1_KD (purple) cells treated with 0, 5nM, or 12.5nM gemcitabine. Sample size ranges from 4 to 11 per condition. P-value asterisks: ≤0.001=*** & ≤0.0001=****, unpaired, two-tailed parametric t-tests